Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1979 Apr;32(4):325–333. doi: 10.1136/jcp.32.4.325

Studies of plasma zinc, copper, caeruloplasmin, and growth hormone

With special reference to carcinoma of the bronchus

G S Andrews 1
PMCID: PMC1145668  PMID: 447867

Abstract

The levels of plasma zinc, copper, caeruloplasmin, and growth hormone were determined in a group of normal people and in four groups of patients who were suffering from carcinoma of the bronchus, other forms of malignancy, chest illnesses, and diseases other than chest illness or malignancy. The plasma zinc was higher, and the plasma copper lower, in people without malignancy below the age of 30 years than they were in other age groups.

It was confirmed that about 66% of patients with carcinoma of the bronchus had plasma zinc levels less than 11·5 μmol/l but low levels were also found in 23% of other cases of malignancy and in 9% of the other patients. In carcinoma of the bronchus the low plasma zinc was found to be associated with epidermoid and anaplastic tumours and was to some extent related to the duration of the disease.

In carcinoma of the bronchus the plasma copper was found to be higher than in all other groups, and values higher than 26·5 μmol/l were considered to support a diagnosis of carcinoma of the bronchus. There was, however, no relationship between the increase in the plasma copper and the decrease in the plasma zinc.

Raised caeruloplasmin levels above 420 mg/l were found in 65% of cases of carcinoma of the bronchus, and these high levels were usually associated with raised plasma copper. Growth hormone was normal in all groups except six patients with carcinoma of the bronchus with secondary carcinoma of the liver, in whom it was raised. Surgical operations lowered plasma zinc and raised growth hormone but did not affect plasma copper.

A plasma zinc below 11·5 μmol/l is helpful in the diagnosis of carcinoma of the bronchus, but by itself it is not sufficiently specific to be considered diagnostic or to form a reliable screening test. A raised plasma copper and a raised plasma caeruloplasmin were useful supportive findings.

Full text

PDF
325

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beck C., Burger H. G. Evidence for the presence of immunoreactive growth hormone in cancers of the lung and stomach. Cancer. 1972 Jul;30(1):75–79. doi: 10.1002/1097-0142(197207)30:1<75::aid-cncr2820300112>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  2. Beeley J. M., Darke C. S., Owen G COOPER R. D. Serum zinc, bronchiectasis, and bronchial carcinoma. Thorax. 1974 Jan;29(1):21–25. doi: 10.1136/thx.29.1.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Davies I. J., Musa M., Dormandy T. L. Measurements of plasma zinc. II. In malignant disease. J Clin Pathol. 1968 May;21(3):363–365. [PMC free article] [PubMed] [Google Scholar]
  4. Davies I. J. Plasma-zinc concentration in patients with bronchogenic carcinoma. Lancet. 1972 Jan 15;1(7742):149–149. doi: 10.1016/s0140-6736(72)90717-9. [DOI] [PubMed] [Google Scholar]
  5. Greaves M. W., Skillen A. W. Effects of long-continued ingestion of zinc sulphate in patients with venous leg ulceration. Lancet. 1970 Oct 31;2(7679):889–891. doi: 10.1016/s0140-6736(70)92066-0. [DOI] [PubMed] [Google Scholar]
  6. Griffith K., Wright E. B., Dormandy T. L. Tissue zinc in malignant disease. Nature. 1973 Jan 5;241(5384):60–60. doi: 10.1038/241060a0. [DOI] [PubMed] [Google Scholar]
  7. Hallbök T., Lanner E. Serum-zinc and healing of venous leg ulcers. Lancet. 1972 Oct 14;2(7781):780–782. doi: 10.1016/s0140-6736(72)92143-5. [DOI] [PubMed] [Google Scholar]
  8. Halsted J. A., Smith J. C., Jr Plasma-zinc in health and disease. Lancet. 1970 Feb 14;1(7642):322–324. doi: 10.1016/s0140-6736(70)90701-4. [DOI] [PubMed] [Google Scholar]
  9. Husain S. L. Oral zinc sulphate in leg ulcers. Lancet. 1969 May 31;1(7605):1069–1071. doi: 10.1016/s0140-6736(69)91706-1. [DOI] [PubMed] [Google Scholar]
  10. JENSEN K. B., THORLING E. B., ANDERSEN C. J. SERUM COPPER IN HODGKIN'S DISEASE. Scand J Haematol. 1964;1:63–74. doi: 10.1111/j.1600-0609.1964.tb00006.x. [DOI] [PubMed] [Google Scholar]
  11. Kokkola K., Tani P. Serum hexosamine and its correlations with serum iron, copper, and iron-binding capacity in bronchogenic pulmonary carcinoma. Scand J Respir Dis Suppl. 1972;80:137–141. [PubMed] [Google Scholar]
  12. Kolarić K., Roguljić A., Fuss V. Serum copper levels in patients with solid tumors. Tumori. 1975 Mar-Apr;61(2):173–177. doi: 10.1177/030089167506100205. [DOI] [PubMed] [Google Scholar]
  13. Lipton A., Sheehan L., Harvey H. A. Urinary polyamine levels in patients with gastrointestinal malignancy. Cancer. 1975 Dec;36(6 Suppl):2351–2354. doi: 10.1002/1097-0142(197512)36:6<2351::aid-cncr2820360612>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  14. Marton L. J., Russell D. H., Levy C. C. Measurement of putrescine, spermidine, and spermine in physiological fluids by use of an amino acid analyzer. Clin Chem. 1973 Aug;19(8):923–926. [PubMed] [Google Scholar]
  15. McBean L. D., Smith J. C., Jr, Berne B. H., Halsted J. A. Serum zinc and alpha2-macroglobulin concentration in myocardial infarction, decubitus ulcer, multiple myeloma, prostatic carcinoma, Down's syndrome and nephrotic syndrome. Clin Chim Acta. 1974 Jan 19;50(1):43–51. doi: 10.1016/0009-8981(74)90076-x. [DOI] [PubMed] [Google Scholar]
  16. Morgan J. M. Cadmium and zinc abnormalities in bronchogenic carcinoma. Cancer. 1970 Jun;25(6):1394–1398. doi: 10.1002/1097-0142(197006)25:6<1394::aid-cncr2820250619>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  17. PAGLIARDI E., GIANGRANDI E. Clinical significance of the blood copper in Hodgkin's disease. Acta Haematol. 1960 Oct;24:201–212. doi: 10.1159/000206463. [DOI] [PubMed] [Google Scholar]
  18. Pories W. J., Henzel J. H., Rob C. G., Strain W. H. Acceleration of wound healing in man with zinc sulphate given by mouth. Lancet. 1967 Jan 21;1(7482):121–124. doi: 10.1016/s0140-6736(67)91031-8. [DOI] [PubMed] [Google Scholar]
  19. Russell D. H. Clinical relevance of polyamines as biochemical markers of tumor kinetics. Clin Chem. 1977 Jan;23(1):22–27. [PubMed] [Google Scholar]
  20. Russell D. H., Russell S. D. Relative usefulness of measuring polyamines in serum, plasma, and urine as biochemical markers of cancer. Clin Chem. 1975 Jun;21(7):860–863. [PubMed] [Google Scholar]
  21. SAVLOV E. D., STRAIN W. H., HUEGIN F. Radiozinc studies in experimental wound healing. J Surg Res. 1962 May;2:209–212. doi: 10.1016/s0022-4804(62)80065-1. [DOI] [PubMed] [Google Scholar]
  22. Schapira M. The presence of caeruloplasmin in cancer of the breast and female genital organs. J R Coll Gen Pract. 1972 Jun;22(119):383–386. [PMC free article] [PubMed] [Google Scholar]
  23. Serjeant G. R., Galloway R. E., Gueri M. C. Oral zinc sulphate in sickle-cell ulcers. Lancet. 1970 Oct 31;2(7679):891–892. doi: 10.1016/s0140-6736(70)92067-2. [DOI] [PubMed] [Google Scholar]
  24. Shifrine M., Fisher G. L. Ceruloplasmin levels in sera from human patients with osteosarcoma. Cancer. 1976 Jul;38(1):244–248. doi: 10.1002/1097-0142(197607)38:1<244::aid-cncr2820380136>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  25. Sinha S. N., Gabrieli E. R. Serum copper and zinc levels in various pathologic conditions. Am J Clin Pathol. 1970 Oct;54(4):570–577. doi: 10.1093/ajcp/54.4.570. [DOI] [PubMed] [Google Scholar]
  26. Sirbu P., Motoiu V., Butte V., Filipesco D., Radulesco I., Vrejoiu V. Etude de la cuprémie comme test de dépistage précoce dans les dysplasies aggravées et dans le cancer du col utérin. Rev Fr Gynecol Obstet. 1972 Oct;67(10):565–569. [PubMed] [Google Scholar]
  27. Solomon N., Copeland E. M., MacFadyen B. V., Jr, Dudrick S. J., Samaan N. A. Intravenous hyperalimentation and growth hormone in cancer patients. Surg Forum. 1974;25(0):59–60. [PubMed] [Google Scholar]
  28. Steiner H., Dahlbäck O., Waldenström J. Ectopic growth-hormone production and osteoarthropathy in carcinoma of the bronchus. Lancet. 1968 Apr 13;1(7546):783–785. doi: 10.1016/s0140-6736(68)92229-0. [DOI] [PubMed] [Google Scholar]
  29. Strain W. H., Mansour E. G., Flynn A., Pories W. J., Tomaro A. J., Hill O. A., Jr Plasma-zinc concentration in patients with bronchogenic cancer. Lancet. 1972 May 6;1(7758):1021–1022. doi: 10.1016/s0140-6736(72)91199-3. [DOI] [PubMed] [Google Scholar]
  30. Tani P., Kokkola K. Serum iron, copper, and iron-binding capacity in bronchogenic pulmonary carcinoma. Scand J Respir Dis Suppl. 1972;80:121–128. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES